|
1
|
Michel MC: Words of wisdom: Re: a
randomized controlled study of the efficacy of tamsulosin
monotherapy and its combination with mirabegron for overactive
bladder induced by benign prostatic obstruction. Eur Urol.
69:174–179. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Li H, Yang J, Zhao H, Fossler MJ and Wang
C: Effect of tamsulosin on the pharmacokinetics of dutasteride in
Chinese male healthy volunteers. Clin Pharmacol Drug Dev.
4:427–433. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Dimitropoulos K and Gravas S: Fixed-dose
combination therapy with dutasteride and tamsulosin in the
management of benign prostatic hyperplasia. Ther Adv Urol. 8:19–28.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kaplan SA: Re: comparison of tamsulosin
plus serenoa repens with tamsulosin in the treatment of benign
prostatic hyperplasia in Korean men: 1-year randomized open label
study. J Urol. 196:503–505. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Nazir J, Heemstra L, van Engen A, Hakimi Z
and Ivanescu C: Cost-effectiveness of a fixed-dose combination of
solifenacin and oral controlled adsorption system formulation of
tamsulosin in men with lower urinary tract symptoms associated with
benign prostatic hyperplasia. BMC Urol. 15:41–45. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Traish AM, Haider KS, Doros G and Haider
A: Finasteride, not tamsulosin, increases severity of erectile
dysfunction and decreases testosterone levels in men with benign
prostatic hyperplasia. Horm Mol Biol Clin Investig. 23:85–96.
2015.PubMed/NCBI
|
|
7
|
Udeh EI, Ofoha CG, Adewole DA and Nnabugwu
II: A cost effective analysis of fixed-dose combination of
dutasteride and tamsulosin compared with dutasteride monotherapy
for benign prostatic hyperplasia in Nigeria: a middle income
perspective; using an interactive Markov model. BMC Cancer.
16:4052016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Stojanović N, Ignjatović I, Djenić N and
Bogdanović D: Adverse effects of pharmacological therapy of benign
prostatic hyperplasia on sexual function in men. Srp Arh Celok Lek.
143:284–289. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kosilov KV, Loparev SA, Ivanovskaya MA and
Kosilova LV: Effectiveness of solifenacin and trospium for managing
of severe symptoms of overactive bladder in patients with benign
prostatic hyperplasia. Am J Men Health. 10:157–163. 2016.
View Article : Google Scholar
|
|
10
|
Russo A, Capogrosso P, La Croce G,
Ventimiglia E, Boeri L, Briganti A, Damiano R, Montorsi F and
Salonia A: Serenoa repens, selenium and lycopene to manage lower
urinary tract symptoms suggestive for benign prostatic hyperplasia.
Expert Opin Drug Saf. 15:1661–1670. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Krivoborodov GG and Tur EI: Long-term
outcomes of the use of α-blockers tamsulosin in men with lower
urinary tract symptoms and benign prostatic hyperplasia. Urologiia.
1247–48. (50)2014.(In Russian).
|
|
12
|
Karami H, Hassanzadeh-Hadad A and
Fallah-Karkan M: Comparing monotherapy with tadalafil or tamsulosin
and their combination therapy in men with benign prostatic
hyperplasia: a randomized clinical trial. Urol J. 13:2920–2926.
2016.PubMed/NCBI
|
|
13
|
Barkin J, Diles D, Franks B and Berner T:
Alpha blocker monotherapy versus combination therapy with
antimuscarinics in men with persistent LUTS refractory to
alpha-adrenergic treatment: patterns of persistence. Can J Urol.
22:7914–7923. 2015.PubMed/NCBI
|
|
14
|
Fusco F, Palmieri A, Ficarra V, Giannarini
G, Novara G, Longo N, Verze P, Creta M and Mirone V: α1-blockers
improve benign prostatic obstruction in men with lower urinary
tract symptoms: a systematic review and meta-analysis of urodynamic
studies. Eur Urol. 69:1091–1101. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Utsunomiya N, Matsumoto K, Tsunemori H,
Muguruma K, Kawakita M, Kamiyama Y, Kanamaru S, Ito N, Tsukazaki H,
Shirahase T, et al: A crossover comparison study on lower urinary
tract symptoms with overactive bladder secondary to benign
prostatic hyperplasia: naftopidil versus tamsulosin with
solifenacin. Hinyokika Kiyo. 62:341–347. 2016.(In Japanese).
PubMed/NCBI
|
|
16
|
Latil A, Pétrissans MT, Rouquet J, Robert
G and de la Taille A: Effects of hexanic extract of serenoa repens
(Permixon® 160 mg) on inflammation biomarkers in the
treatment of lower urinary tract symptoms related to benign
prostatic hyperplasia. Prostate. 75:1857–1867. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Choi JD, Kim JH and Ahn SH: Transitional
zone index as a predictor of the efficacy of α-blocker and
5α-reductase inhibitor combination therapy in Korean patients with
benign prostatic hyperplasia. Urol Int. 96:406–412. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Takeshita H, Moriyama S, Arai Y, Washino
S, Saito K, Chiba K, Horiuchi S and Noro A: Randomized crossover
comparison of the short-term efficacy and safety of single
half-dose silodosin and tamsulosin hydrochoride in men with lower
urinary tract symptoms secondary to benign prostatic hyperplasia.
Low Urin Tract Symptoms. 8:38–43. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Terakado M, Suzuki H, Hashimura K, Tanaka
M, Ueda H, Kohno H, Fujimoto T, Saga H, Nakade S, Habashita H, et
al: Discovery of ONO-7300243 from a novel class of lysophosphatidic
acid receptor 1 antagonists: from hit to lead. ACS Med Chem Lett.
7:913–918. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Seftel AD: Re: finasteride, not
tamsulosin, increases severity of erectile dysfunction and
decreases testosterone levels in men with benign prostatic
hyperplasia. J Urol. 195:1392016. View Article : Google Scholar : PubMed/NCBI
|
